Allogeneic CAR T-cell therapy with ALLO-715 (anti-BCMA) and ALLO-647 (anti-CD52) was well tolerated and showed promising activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
In this updated analysis, patients with a greater proportion of T-cells exhibiting a memory-like phenotype experienced greater CAR T-cell expansion and more durable responses.
Preliminary data from phase I/II study on novel CAR T-cell therapy, P-BCMA-101, suggest safe and effective treatment for relapsed and refractory multiple myeloma.
One-year outcomes from the phase II DREAMM-2 trial showed comparable outcomes with belantamab mafodotin in patients with R/R MM after either 3-6 or ≥ 7 prior lines of therapy.
Preliminary analysis reported manageable safety profile and clinical activity with belantamab mafodotin plus bortezomib/dexamethasone in ongoing phase II trial of pretreated patients with MM.
In patients with R/R MM receiving belantamab mafodotin, ocular AEs were common but manageable, with the majority of patients recovering while remaining on treatment.
Initial results from the phase Ib/II study suggest ciltacabtagene autoleucel, an anti-BCMA CAR T-cell therapy, showed promising efficacy and a manageable safety profile in heavily pretreated patients with R/R MM.
In this early study, the anti-BCMA ADC MEDI228 had manageable toxicity with responses seen at all dose levels in patients with heavily pretreated, relapsed/refractory multiple myeloma.
Subcutaneous administration of teclistamab (JNJ-64007957) was well tolerated and associated with high response rates at the RP2D in an ongoing phase I trial of heavily pretreated patients with multiple myeloma.
Initial results from this ongoing phase I study suggest that once-weekly administration of AMG 701 yields encouraging activity with the possibility for deep, durable responses, along with a manageable safety profile.
After 4 years of follow-up, addition of daratumumab to lenalidomide/dexamethasone reduced the risk of progression or death by 46% and tripled the rate of MRD negativity.
Bispecific antibody targeting GPCR5D, talquetamab, appears tolerable, safe, and efficacious in phase I data in patients with heavily pretreated relapsed/refractory MM.
In this early study, anti-BCMA bispecific antibody REGN5458 showed promising efficacy and safety in heavily pretreated patients with R/R MM.
Novel bispecific antibody targeting FcRH5, cevostamab, active and tolerable in heavily pretreated patients with R/R MM
APOLLO met its primary endpoint of significantly improved PFS with daratumumab SC + Pd vs Pd only in patients with relapsed/refractory MM previously treated with lenalidomide and a PI.
Data from the maintenance phase of GRIFFIN trial with D-VRd + DR maintenance led to significant improvement in sCR and depth of response vs VRd + R maintenance.
The addition of ixazomib to Rd was reasonably well tolerated and conferred a clinically meaningful, but not statistically significant 13.5-month improvement in PFS compared with the control arm.
The first clinical results of iberdomide in combination with either daratumumab/dex or bortezomib/dex is well tolerated with encouraging efficacy in heavily pretreated patients with myeloma.
Combination of belantamab mafodotin with pomalidomide/dexamethasone resulted in high response rates in patients with relapsed/refractory multiple myeloma.
All-oral regimen of selinexor/pomalidomide/low-dose dexamethasone appears to be highly active and have a manageable safety profile in patients with R/R MM after ≥ 2 previous therapies.